Evidence map›Paper›PMID 26000051›Full record

ArticleJournal of Cancer2015

In Vitro Administration of Gold Nanoparticles Functionalized with MUC-1 Protein Fragment Generates Anticancer Vaccine Response via Macrophage Activation and Polarization Mechanism.

Teodora Mocan, Cristian Matea, Flaviu Tabaran, Cornel Iancu, Remus Orasan, Lucian Mocan

Open access · goldAbstract read
In one paragraph

Article in Journal of Cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 58 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Chemical Sensor Nanotechnology in Pharmaceutical Drug Research.Nanomaterials (Basel, Switzerland) · 2022
    Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Combined strategies for tumor immunotherapy with nanoparticles.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Teodora Mocan2. Department of Nanomedicine, Institute of Gastroenterology and Hepatology, 19-21 Croitorilor St., 400162 Cluj-Napoca, Romania. ; 3. Department of Physiology, "Iuliu Hatieganu" University of Medicine and Pharmacy, no. 1 Clinicilor Street., 400006 Cluj-Napoca, Romania.
Cristian Matea1. 3rd Surgery Clinic, "Iuliu Hatieganu" University of Medicine and Pharmacy, 19-21 Croitorilor St., 400162 Cluj-Napoca, Romania. ; 2. Department of Nanomedicine, Institute of Gastroenterology and Hepatology, 19-21 Croitorilor St., 400162 Cluj-Napoca, Romania.
Flaviu Tabaran2. Department of Nanomedicine, Institute of Gastroenterology and Hepatology, 19-21 Croitorilor St., 400162 Cluj-Napoca, Romania. ; 4. Department of Pathology, Faculty of Veterinary Medicine, University of Agricultural Sciences and Veterinary Medicine, Cluj-Napoca, Romania; Calea Mănăștur 3-5, Cluj-Napoca 400372.
Cornel Iancu1. 3rd Surgery Clinic, "Iuliu Hatieganu" University of Medicine and Pharmacy, 19-21 Croitorilor St., 400162 Cluj-Napoca, Romania. ; 2. Department of Nanomedicine, Institute of Gastroenterology and Hepatology, 19-21 Croitorilor St., 400162 Cluj-Napoca, Romania.
Remus Orasan3. Department of Physiology, "Iuliu Hatieganu" University of Medicine and Pharmacy, no. 1 Clinicilor Street., 400006 Cluj-Napoca, Romania.
Lucian Mocan1. 3rd Surgery Clinic, "Iuliu Hatieganu" University of Medicine and Pharmacy, 19-21 Croitorilor St., 400162 Cluj-Napoca, Romania. ; 2. Department of Nanomedicine, Institute of Gastroenterology and Hepatology, 19-21 Croitorilor St., 400162 Cluj-Napoca, Romania.
Iuliu Hațieganu University of Medicine and Pharmacy · ROUniversity of Agricultural Sciences and Veterinary Medicine of Cluj-Napoca · RO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Therapeutic cancer vaccines (or active immunotherapy) aim to guide the patient's personal immune system to eradicate cancer cells. An exciting approach to cancer vaccines has been offered by nanoscale drug delivery systems containing tumor associated antigens (TAAs). Their capacity to stimulate the immune system has been suggested during late years. However, the role of the macrophages as key-elements in antigen-presentation process following TAAs-containing nanosystems is not completely understood. We aimed to evaluate the effect of gold nanoparticles functionalized with mucin-1 peptide (MUC-1) on murine peritoneal macrophages. Gold nanoparticles, obtained using a modified Turkevich method, were functionalized with MUC-1 protein using Clealand's reagent. The obtained GNP-MUC-1 solution was used to treat at various concentrations monolayers of peritoneum-derived macrophages that were further analyzed using confocal and hyperspectral microscopy, ELISA assays and spectroscopic techniques. The GNP-MUC-1 nano-construct had proven to function as a powerful macrophage activator with consequent release of cytokines such as: TNF-ɑ, IL-6, IL-10 and IL-12 on peritoneal macrophages we have isolated from mice. Our results demonstrate optimization of antigen-presenting process and predominant M1 polarization following exposure GNP-MUC-1. To our best knowledge this is the first study to evaluate the anticancer effects of a newly designed nano-biocompound on the complex antigen- processing apparatus of peritoneal macrophages.

Indexed as

cancer vaccinemacrophagesmonoclonal antibodiespeptides

Identifiers

PMID26000051
PMCPMC4439945
OpenAlexW2159471336

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.